Mr. Chris Boland was appointed as Chief Financial Officer of Avivagen Inc., with effect from July 12, 2012
CFO Since 2012Boland is a Canadian chartered accountant and also holds the certified management accountant designation. Prior to his present appointment, Mr. Boland was in public practice . Earlier positions at other organizations include general manager at Canada Post Corporationrationrationration, chief financial officer and vicepresident finance at Optiwave Corporationrationrationration, director of tax and treasury, controller, at Eftia OSS, manager of financial reporting and controller at the Canadian Bank Note, and manager of financial reporting at Mitel Corporationrationrationration. He was also an auditor at the Office of the Auditor General and manager at Treasury Board.
Management EfficiencyThe company has return on total asset (ROA) of (57.97) % which means that it has lost $57.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (312.77) % meaning that it generated substantial loss on money invested by shareholders.
Entity SummaryAvivagen, Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animals own health defenses. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen, Inc. in May 2012. Avivagen is traded on TSX Venture Exchange in Canada.Avivagen (VIV) is traded on TSX Venture Exchange in Canada. It is located in 100 Sussex Drive and employs 19 people.
Avivagen Leadership Team
Stock Performance Indicators
Also Currentnly Active
Purchased over 300 shares of
Purchased over 70 shares of